ACVR1
Activin receptor type-1
As of the edition of 20 October 2026, ACVR1 (activin receptor type-1, UniProt Q04771) has 7 drugs tested at it and 6 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q04771
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 85
- Disease areas
- Blood and lymph; Cancer; Bones, joints and muscles; Mouth and teeth; Heart and blood vessels; Nutrition and metabolism; Hormones; Immune system
- Registered trials of its drugs
- 42
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Momelotinib | Marketed | Phase 3 | Ends 2035 |
| Dibotermin alfa | Marketed | Phase 4 | none listed |
| Zilurgisertib | Active | Phase 2 | none listed |
| Bone morphogenetic protein 2 | Went quiet | Phase 2 | none listed |
| Fidrisertib | Stopped | Phase 2 | none listed |
| TP-0184 | Stopped | Phase 2 | none listed |
| Eptotermin alfa | Withdrawn from market | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| GSK | Route B |
| Sumitomo Pharma | Route A |
The other 4 companies at ACVR1
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at ACVR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.